MYB-NFIB fusion transcript in adenoid cystic carcinoma: Current state of knowledge and future directions

Crit Rev Oncol Hematol. 2022 Aug:176:103745. doi: 10.1016/j.critrevonc.2022.103745. Epub 2022 Jun 20.

Abstract

Adenoid cystic carcinoma (ACC) is the most common type of salivary gland cancer that can also arise in other primary sites. Regardless of the site, most ACC cases carry a recurrent chromosomal translocation - t(6;9)(q22-23;p23-24) - involving the MYB oncogene and the NFIB transcription factor. Generally, a long sequence of MYB is fused to the terminal exons of NFIB, yet the break can occur in different exons for both genes, resulting in multiple chimeric variants. The fusion status can be determined by a number of methods, each of them with particular advantages. In vitro and in vivo studies have been conducted to understand the biological consequences of MYB-NFIB translocation, and such findings could contribute to improving the current inefficient therapeutic options for disseminated ACC. This review provides a discussion on relevant evidence in the context of ACC MYB-NFIB translocations to determine the current state of knowledge and discuss future directions.

Keywords: Chromosomal translocation; Fusion proteins; Head and neck neoplasms; Oncogenes; Salivary gland tumors.

Publication types

  • Review

MeSH terms

  • Carcinoma, Adenoid Cystic* / genetics
  • Carcinoma, Adenoid Cystic* / pathology
  • Gene Fusion
  • Humans
  • NFI Transcription Factors / genetics
  • Oncogene Proteins, Fusion / genetics
  • Proto-Oncogene Proteins c-myb
  • Salivary Gland Neoplasms* / diagnosis
  • Salivary Gland Neoplasms* / genetics
  • Salivary Gland Neoplasms* / therapy
  • Translocation, Genetic

Substances

  • MYB protein, human
  • MYB-NFIB fusion protein, human
  • NFI Transcription Factors
  • NFIB protein, human
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Proteins c-myb